The Cutting Edge of Gastroenteritis

Arostegui, Dalia; Wallach, Thomas

doi:10.1097/mpg.0000000000003304

Cited by 5 publications

(2 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ondansetron is a 5-HT3 receptor antagonist that blocks the vagal stimulation induced by 5-HT4, which reduces gut motility and secretion and thus reducing nausea and vomiting (8). Ondansetron is frequently used in combination with oral rehydration therapy in children with vomiting secondary to acute gastroenteritis and has been found in multiple studies and 1 meta-analysis, to be highly safe and effective (8)(9)(10)(11)(12). While serotonin is involved in intestinal motility, and constipation has been reported as a side effect of Ondansetron in a study by Bryson (13) in 7% of patients, initial toxicity work noted diarrhea as a side effect in 9% of patients (14).…”

Section: What Is Newmentioning

confidence: 99%

Pilot Study of Ondansetron in Improvement of Pediatric Colonoscopy Preparation Outcomes at an Urban Academic Center

Arostegui,

Armaly,

Castro Ochoa

et al. 2023

JPGN Reports

Self Cite

View full text Add to dashboard Cite

Objectives: To gather initial data on the effectiveness and tolerability of the addition of Ondansetron to bowel preparation regimens to justify a funded, larger, placebo-controlled study. Methods: Design, Setting, and Participants: A total of 41 pediatric and young adult (age 2–22) patients participated in a single center, open label, parallel randomized trial, with simple randomization. All patients were recruited as outpatients, and all procedures occurred as outpatient procedures, with both recruitment and procedures occurring at a low-resource urban academic medical center in Brooklyn. Interventions and Outcome Measures: The intervention studied was a single dose of oral-dissolving tablet Ondansetron provided before initiation of bowel preparation using a standardized prep of Polyethylene Glycol 3350 and Bisacodyl. There were 2 arms, a study arm using typical preparation (Polyethylene Glycol 3350 and Bisacodyl) and Ondansetron, and a control arm (Polyethylene Glycol 3350 and Bisacodyl). Patients received standard weight-based dosing. The primary outcome measure assessed was the Boston Bowel Preparation Scale (BBPS) to assess efficacy of preparation. Secondary objectives included evaluation of patient satisfaction via a survey answered by each patient. The questionnaire assessed the presence of the following symptoms during bowel prep: abdominal pain, nausea, bloating, vomiting, scale of ease/difficulty, and if the entire bowel prep was completed. Results: No benefit to BBPS from the addition of Ondansetron to bowel preparation was observed. Statistically significant improvement in reports of abdominal pain (35% decrease in Ondansetron arm) was noted with a P = 0.019. No statistically significant improvement was noted in other symptoms although all domains showed nonsignificant improvement in the Ondansetron arm. Conclusion: No benefit to efficacy of preparation as measured by the BBPS was observed. A single dose of Ondansetron before bowel preparation reduced reports of abdominal pain by 35%, with other symptomatic improvements suggesting possible improvements to be confirmed by a higher-powered study. Trial registration: NCT05439772.

show abstract

Section: What Is Newmentioning

confidence: 99%

Pilot Study of Ondansetron in Improvement of Pediatric Colonoscopy Preparation Outcomes at an Urban Academic Center

Arostegui,

Armaly,

Castro Ochoa

et al. 2023

JPGN Reports

Self Cite

View full text Add to dashboard Cite

show abstract

“…The condition normally lasts from 1 to 2 weeks if unchecked may even become persistent from 14-30 days 1,2 . The side effects include fever, dehydration and headache which lasts to couple of weeks [3][4][5] .…”

mentioning

confidence: 99%

Untitled

2023

IJPSR

View full text Add to dashboard Cite

Acute gastroenteritis prevalent amongst children and newborns is considered a serious infection globally. The Acute diarrhea as a result of gastroenteritis as per logistics suggest that there were more than 1.5 million outpatient visits along with 200,000 hospitalizations and 300 fatalities per year in children in U.S. Diarrhea is the leading cause of deaths amongst children with 30% relapse rate. The viral gastroenteritis caused by the Rotavirus is one the significant strain contributing the gastroenteritis. The suggestive therapies include Oral rehydration therapy (ORT) respective to age modulating the diet and ORS solutions. The gastroenteritis condition cannot be neglected but can be considered as significant public health issue especially in the elder patients with fatality ratio compared to children. The diagnosis of gastroenteritis includes signs, symptoms and stool cultures. The comorbidities in the patients when treated with variety of drugs is resulting damage of stomach lining and worsening the conditions of gastroenteritis. The comorbidities include the cardiovascular diseases, kidney related diseases and other infections playing major role for the chronic condition. There is need of clinical intervention for improvement of treatment, prevent reoccurrence and suggest the antibiotic rational use in the patients with comorbidities. The present review has represented the global data of infection causing agents, contributing factors of comorbidities leading to gastroenteritis, diagnosis and alternative treatment. The need of change in diet and rationale use of antibiotics is best measure to prevent the relapse of disease leading to less hospitalizations. The support from the alternative systems of medicine was suggested to improve the patient condition and also to prevent the reoccurrence. INTRODUCTION:Acute gastroenteritis infection is considered as one of the most serious illnesses leading to deaths in children globally causing severe vomiting. The gastroenteritis has led to 1.4 to 2.5 million deaths per year during 2021. The condition of gastroenteritis is condition caused with or without symptoms of nausea, vomiting and diarrhea.

show abstract

Synthesis and Antiviral Efficacy of Pyrimidine Analogs Targeting Viral Pathways

Basha¹,

Chandana²

2023

ChemistrySelect

View full text Add to dashboard Cite

To date, viruses are known to cause chronic to acute pathogenesis. Nevertheless, antiviral drugs have been known for their medicinal applications for the last few decades to treat infections caused by these pathogens. Despite advancements in the field of vaccination and antiviral drugs, there is a need for a molecule that can eradicate or control viral infection without getting resistance from pathogens will be a real challenge. This review covers possible ways to treat viral infections with pyrimidine and its mimics compared to known antiviral drugs. A comprehensive study of the report accomplished synthetic routes of pyrimidine analogs and their target‐specific antiviral potential. The present review article covers literature from 2018 to 2022.

show abstract

The Cutting Edge of Gastroenteritis

Cited by 5 publications

References 61 publications

Pilot Study of Ondansetron in Improvement of Pediatric Colonoscopy Preparation Outcomes at an Urban Academic Center

Pilot Study of Ondansetron in Improvement of Pediatric Colonoscopy Preparation Outcomes at an Urban Academic Center

Untitled

Synthesis and Antiviral Efficacy of Pyrimidine Analogs Targeting Viral Pathways

Contact Info

Product

Resources

About